Results 121 to 130 of about 1,005 (173)

Comments on: "The Utility of Betahistine Dihydrochloride, a Structural Analog of Histamine, in Clozapine-Associated Daytime Sedation: A Case Series". [PDF]

Indian J Psychol Med
Ajay S, Munipati D, Tikka SK.
europepmc   +1 more source

The cost utility of pitolisant as narcolepsy treatment

Acta Neurologica Scandinavica, 2020
The cost-effectiveness of available pharmacological treatments for narcolepsy is largely unknown. Available pharmacological treatments are associated with tolerability, abuse, and adherence issues. Pitolisant is the first inverse agonist of the histamine H3 receptor to be prescribed for the treatment of narcolepsy with and without cataplexy.
KRISTIAN Bolin, Laura Pirhonen, Pontus Wasling   +2 more
exaly   +5 more sources

Pharmacokinetics of pitolisant in children and adolescents with narcolepsy

Sleep Medicine, 2020
To evaluate the pharmacokinetic profile and tolerability of pitolisant, a selective histamine 3 (H3)-receptor antagonist/inverse agonist, in children and adolescents with narcolepsy.This multicenter, open-label, single-dose study of pitolisant 17.8 mg enrolled patients aged 6 through 17 years with a diagnosis of narcolepsy. Blood samples were collected
Michel Lecendreux, Giuseppe Plazzi, Patricia Franco   +2 more
exaly   +6 more sources

Action of Pitolisant on the stimulant and rewarding effects of cocaine in mice

European Journal of Pharmacology, 2016
Previous studies have demonstrated that the histamine H3 receptor inverse agonist thioperamide potentiates the stimulant and rewarding effects of cocaine. However, these potentiating effects of thioperamide do not necessarily result from H3 receptor blockade since thioperamide is an imidazole-based compound capable of enhancing plasma cocaine ...
Maria Elisa Serrano, Ezio Tirelli
exaly   +5 more sources

Evaluating pitolisant as a narcolepsy treatment option

Expert Opinion on Pharmacotherapy, 2020
Narcolepsy is a chronic sleep disorder characterized by a pentad of excessive daytime sleepiness (EDS), cataplexy, sleep paralysis, hypnagogic/hypnopompic hallucinations, and disturbed nocturnal sleep. Treatment of narcolepsy remains challenging and current therapy is strictly symptomatically based.The present manuscript is based on an extensive ...
de Biase S., Pellitteri G., Gigli G. L., Valente M.   +3 more
openaire   +3 more sources

Exploring Polymorphism: Hydrochloride Salts of Pitolisant and Analogues [PDF]

Crystal Growth & Design
Pitolisant hydrochloride is used to treat excessive daytime sleepiness in adults with narcolepsy. The drug is formulated as a crystalline solid, and a monoclinic P21 form has been claimed in patents, but little additional information about the structure and polymorphism of the compound has been published.
Jessica Patel, Zachary Leduc, Aaron Gabriel Nunez Avila, Joseph A. Glover, Kelin Wu, Yuxing Zhang, Jing Zhang, Xiaoting Zhai, Huize Jing, Alex M. Chen, Daniel Chartrand, Thierry Maris, Graeme M. Day, James D. Wuest   +13 more
core   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Pitolisant for treating patients with narcolepsy

Expert Review of Clinical Pharmacology, 2020
Introduction: Narcolepsy is a rare sleep disorder characterized by excessive daytime sleepiness, cataplexy, disturbed nocturnal sleep, hypnagogic hallucinations, and sleep paralysis. Pitolisant is a first-in-class drug acting on histamine 3 receptors and indicated for the treatment of narcolepsy. This article aims to review pitolisant.Areas covered: In
Junyi Yang
exaly   +3 more sources